| Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers (NCT03060447) | Gilead Sciences | 2017-05-09 |
| Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection (NCT03399903) | AIDS Healthcare Foundation | 2017-05-01 |
| National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) Infection (NCT02987530) | ANRS, Emerging Infectious Diseases | 2017-04-11 |
| Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria (NCT03087890) | University of Bergen | 2017-03-30 |
| PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332) (NCT03070223) | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 2017-03-14 |
| Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV (NCT03129113) | University College, London | 2017-03-01 |
| Pertussis Immunization During Pregnancy & HIV Infection (NCT03519373) | Centre Hospitalier Universitaire Saint Pierre | 2017-03-01 |
| VIH-1 Colo-rectal Transmission by Infected Semen Cells and Effects of Seminal Plasma ex Vivo (CellspermVIH) (NCT03075397) | University Hospital, Toulouse | 2017-02-27 |
| Gut-Associated Lymphocyte Trafficking (NCT02906137) | ANRS, Emerging Infectious Diseases | 2017-02-06 |
| Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE) (NCT03493568) | IRCCS San Raffaele | 2017-02-06 |
| The Partners Scale-Up Project (NCT03052010) | University of Washington | 2017-02-06 |
| Measurement for Viral Reservoir and Immune Function in HIV-1-infected Patients Under Antiretroviral Therapy (NCT04068441) | National Taiwan University Hospital | 2017-01-28 |
| Early ART to Limit Infection and Establishment of Reservoir (NCT02859558) | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 2017-01-24 |
| Impact of HIV-1 and Aging on Mucosal Vaccine Responses (NCT03729778) | VA Eastern Colorado Health Care System | 2017-01-18 |
| ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy (NCT03122262) | Professor Francois Venter | 2017-01-16 |
| HIV Persistence in Lymph Node and Peripheral Blood (NCT03426189) | University of Melbourne | 2017-01-02 |
| A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir (NCT03198884) | Southern Illinois Healthcare Foundation | 2017-01-01 |
| Pilot Study to Assess the Impact of a Mobile Health Application (App) on Clinical Outcomes and Satisfaction of Older HIV-Infected Patients, as an Emerging Tool for Care, Education and Prevention. (NCT04137016) | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 2016-12-15 |
| Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression (NCT03251690) | Mahidol University | 2016-10-27 |
| Gender-Affirmative Transgender Care to Improve the HIV Treatment Cascade (NCT03757117) | Asociación Civil Impacta Salud y Educación, Peru | 2016-10-01 |
| Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1 (NCT02881320) | Gilead Sciences | 2016-09-21 |
| Mathematical Modeling of the HIV Transmission Risk After Initiation of Antiretroviral Therapy in naïve HIV-infected (NCT03183154) | Hospital General Universitario Gregorio Marañon | 2016-08-01 |
| Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings (NCT02777229) | ANRS, Emerging Infectious Diseases | 2016-07-01 |
| Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients (NCT02818348) | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 2016-06-01 |
| Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment (NCT02707601) | Gilead Sciences | 2016-04-01 |
| Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers (NCT02706717) | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 2016-04-01 |
| Effects of Metformin During Nicotine Withdrawal (NCT03593538) | University of Pennsylvania | 2016-04-01 |
| Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (NCT02707900) | University of North Carolina, Chapel Hill | 2016-03-01 |
| Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women (NCT02652624) | Gilead Sciences | 2016-02-19 |
| 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF (NCT02605304) | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 2016-02-17 |
| Prevalence, Characteristics and Risk Factors of HIV-Associated Neurocognitive Disorders in Subjects Between the Ages of 55 and 70 Years: An Exposed/Unexposed Cross Sectional Study (NCT02592174) | ANRS, Emerging Infectious Diseases | 2016-01-26 |
| Analytical Treatment Interruption in HIV Positive Patients (NCT02590354) | Institute of Tropical Medicine, Belgium | 2016-01-25 |
| Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030) (NCT02629822) | Merck Sharp & Dohme LLC | 2016-01-14 |
| Infectious Diseases and Movement Program: Study of the Effects of Physical Activity on HIV Infection (NCT03392805) | University of Roma La Sapienza | 2016-01-01 |
| Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years (NCT02616783) | Gilead Sciences | 2015-12-22 |
| The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation (NCT02581202) | AbbVie | 2015-12-21 |
| Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART) (NCT02440789) | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 2015-12-21 |
| Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I (NCT02616029) | Gilead Sciences | 2015-12-17 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis (NCT02600819) | Gilead Sciences | 2015-12-14 |
| Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients (NCT02582684) | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 2015-12-08 |
| A Mobile Intervention to Promote Cessation in HIV-infected Smokers (NCT02432482) | Montefiore Medical Center | 2015-12-01 |
| Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults (NCT02603107) | Gilead Sciences | 2015-11-20 |
| Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults (NCT02605954) | Gilead Sciences | 2015-11-18 |
| Probiotic Visbiome for Inflammation and Translocation in HIV Ι (NCT02441244) | University Health Network, Toronto | 2015-11-15 |
| Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults (NCT02607930) | Gilead Sciences | 2015-11-13 |
| Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed (NCT02603120) | Gilead Sciences | 2015-11-11 |
| Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults (NCT02607956) | Gilead Sciences | 2015-11-11 |
| PK Study of Rifampicin Interactions With DMPA and Efavirenz in TB (NCT02412436) | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 2015-11-03 |
| Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects (NCT02770508) | Fundación Huésped | 2015-11-01 |
| Study to Assess the ART Impact on the Brain Outcomes. The ARBRE Study (NCT03835546) | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 2015-10-26 |
| Targeting Platelets in Chronic HIV Infection (NCT02578706) | Icahn School of Medicine at Mount Sinai | 2015-10-01 |
| A Study of the Safety and Antiretroviral Activity of 3BNC117 (NCT02588586) | Rockefeller University | 2015-10-01 |
| Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis (NCT02273765) | ANRS, Emerging Infectious Diseases | 2015-09-11 |
| A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia (NCT02542852) | Castagna Antonella | 2015-09-01 |
| Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys (NCT04711265) | Kenya Medical Research Institute | 2015-09-01 |
| Sitagliptin for Reducing Inflammation and Immune Activation (NCT02513771) | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 2015-09-01 |
| Optimising DNA Vaccinations in Healthy Volunteers (NCT03663998) | Imperial College London | 2015-08-15 |
| Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen (NCT02566707) | Radboud University Medical Center | 2015-08-01 |
| Progesterone Supplementation for HIV-positive Pregnant Women on Anti-Retrovirals (NCT02400021) | Mount Sinai Hospital, Canada | 2015-08-01 |
| Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects (NCT02042001) | Azienda Ospedaliera San Gerardo di Monza | 2015-07-01 |
| Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC (NCT02469246) | Gilead Sciences | 2015-06-29 |
| Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (NCT02397096) | Merck Sharp & Dohme LLC | 2015-06-09 |
| To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults (NCT02369146) | United BioPharma | 2015-06-01 |
| Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients (NCT02473328) | Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida | 2015-06-01 |
| HIV Adherence Bottle Intervention Trial (NCT03772327) | Weill Medical College of Cornell University | 2015-05-01 |
| Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients (NCT02390297) | Calimmune, Inc. | 2015-04-01 |
| Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults (NCT02397694) | Gilead Sciences | 2015-03-23 |
| 3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption (NCT02446847) | Rockefeller University | 2015-03-11 |
| Testing the Effect of Raltegravir on Persistent de Novo HIV Infection in Virologic Responders to Antiretroviral Therapy (NCT02611895) | University Hospital, Montpellier | 2015-03-01 |
| Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients (NCT02370979) | University Hospital, Strasbourg, France | 2015-02-01 |
| Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults (NCT02858401) | Gilead Sciences | 2015-01-29 |
| Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL (NCT02212379) | ANRS, Emerging Infectious Diseases | 2015-01-01 |
| Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART (NCT01903031) | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 2014-12-30 |
| Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults (NCT02246998) | Gilead Sciences | 2014-12-15 |
| A Cohort Study to Assess Sustained Immunogenicity to qHPV Vaccine Among HIV-infected Girls and Boys Age 9-14 Years (NCT01446718) | Kenya Medical Research Institute | 2014-12-15 |
| Physiopathology Study of the Microbiota Biodiversity of HIV Seropositive Patients (NCT02116374) | ANRS, Emerging Infectious Diseases | 2014-12-01 |
| Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR) (NCT02247687) | ANRS, Emerging Infectious Diseases | 2014-12-01 |
| Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants (NCT02275065) | Gilead Sciences | 2014-10-24 |
| Researching Alveolar Macrophage Improvements With Supplements in HIV (NCT02264860) | Emory University | 2014-10-01 |
| Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot Study (NCT02211482) | Fundación Huésped | 2014-10-01 |
| Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Ulonivirine (MK-8507) in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003) (NCT02174159) | Merck Sharp & Dohme LLC | 2014-09-15 |
| Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3 (NCT02057796) | ANRS, Emerging Infectious Diseases | 2014-09-01 |
| Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Infected Patients (NCT02732457) | Kirby Institute | 2014-09-01 |
| Efficacy, Safety and Optimal Dose of VM-1500 in Comparison to Efavirenz Added to Standard-of-care Antiretroviral Therapy (NCT02489461) | Viriom | 2014-08-05 |
| Modulation of Immune Activation by Aspirin (NCT02155985) | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 2014-08-01 |
| Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery (NCT01969058) | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 2014-07-02 |
| 4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients (NCT02157311) | ANRS, Emerging Infectious Diseases | 2014-07-01 |
| Evaluation of Raltegravir During the Third Trimester of Pregnancy (NCT02099474) | ANRS, Emerging Infectious Diseases | 2014-06-30 |
| Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection (NCT02128217) | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 2014-05-30 |
| Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF (NCT02121795) | Gilead Sciences | 2014-05-06 |
| Effects of Dolutegravir Based Regimen on HIV-1 Reservoir and Immune Activation (NCT02557997) | University Hospital, Strasbourg, France | 2014-04-01 |
| A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019) (NCT02089659) | Merck Sharp & Dohme LLC | 2014-03-26 |
| Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD) (NCT02067767) | Nantes University Hospital | 2014-02-01 |
| Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected (NCT01632891) | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 2014-01-10 |
| Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density (NCT01966822) | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 2014-01-01 |
| Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study) (NCT01928927) | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 2014-01-01 |
| Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay (NCT02026752) | Gen-Probe, Incorporated | 2014-01-01 |
| Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS (NCT01435018) | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 2013-10-01 |
| Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients (NCT01989910) | Taipei Veterans General Hospital, Taiwan | 2013-09-01 |
| Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV (NCT01935089) | The Wistar Institute | 2013-08-07 |